Form 4: Relay Therapeutics Grants Stock Options to Chief Corporate Development Officer

Relay Therapeutics, Inc. granted 475,000 stock options to Chief Corporate Development Officer Peter Rahmer with an exercise price of $7.94, vesting quarterly after January 13, 2026.

Summary

• Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, Inc., was granted 475,000 stock options.
• The options have an exercise price of $7.94 per share.
• The options will vest in sixteen equal quarterly installments starting after January 13, 2026.
• The expiration date for these options is January 12, 2036.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive sign of management alignment and retention, reflecting confidence in future growth, though it's a routine compensation event rather than a major strategic announcement.

Positives

• The grant of stock options aligns the interests of the Chief Corporate Development Officer with long-term shareholder value.
• The vesting schedule encourages long-term retention and performance from a key executive.
• The transaction was made under a Rule 10b5-1(c) plan, indicating a pre-arranged, non-discretionary transaction.

Negatives

• Potential for future dilution if all options are exercised, although this is standard for equity compensation.

Risks

• The value of the stock options is dependent on the future market price of Relay Therapeutics' common stock exceeding the exercise price of $7.94.
• The reporting person's continued service with the Issuer is required for the options to vest.

Future Outlook

The stock option grant, with its long-term vesting schedule, indicates an expectation of continued service from the Chief Corporate Development Officer and a focus on long-term value creation for the company.

Industry Context

Equity compensation, particularly through stock options with vesting schedules, is a standard practice in the biotechnology and pharmaceutical industry to attract, retain, and incentivize key executives, aligning their performance with company growth and shareholder returns.

Comparison to Industry Standards

• The grant of 475,000 stock options to a Chief Corporate Development Officer is a common form of executive compensation in growth-oriented biotech companies like Relay Therapeutics, similar to practices seen at peers such as Moderna (MRNA) or BioNTech (BNTX) for their executive teams, though the specific number of options varies based on company size, executive role, and compensation philosophy.
• The exercise price of $7.94, likely the closing price on the grant date, is standard for at-the-money options grants.
• A 10-year expiration period (until January 12, 2036) and a multi-year quarterly vesting schedule (16 equal quarterly installments) are typical structures designed to incentivize long-term commitment and performance, comparable to equity incentive plans at companies like Vertex Pharmaceuticals (VRTX) or Regeneron Pharmaceuticals (REGN).

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise, but also potential for increased long-term value creation due to executive incentive.
• Employees: Standard executive compensation practices can positively influence overall employee morale and retention strategies.

Next Steps

• The stock options will begin vesting in sixteen equal quarterly installments after January 13, 2026.
• The reporting person must continue service with the Issuer through each vesting date to receive the shares.

Key Dates

Recommendation

This Form 4 reports a routine executive compensation event, specifically the grant of stock options to a key officer. While it aligns management's interests with shareholders and incentivizes long-term performance, it does not present new fundamental information that would warrant a change in investment thesis. Investors should 'hold' their position and continue to monitor the company's operational performance and broader financial health, as this filing alone does not provide a basis for a 'buy' or 'sell' decision.

Keywords

Relay Therapeutics, RLAY, Stock Options, Form 4, Executive Compensation, Peter Rahmer, Equity Grant, Corporate Development, SEC Filing, Insider Transaction